Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 230
- Registration Number
- NCT05659381
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05655949
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Target Recruit Count
- 40
- Registration Number
- NCT05640791
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2022-12-05
- Target Recruit Count
- 23
- Registration Number
- NCT05637268
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Tianjin Medical University, Tianjin, Tianjin, China
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇰🇷Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, Korea, Republic of
Study of Novel Treatment Combinations in Patients With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 593
- Registration Number
- NCT05633667
- Locations
- 🇧🇷
Hospital Mae de Deus, Porto Alegre, Brazil
🇧🇷Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil
🇬🇧Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabDrug: EtoposideRadiation: Image Guided Radiation TherapyDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- 🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Benefis Sletten Cancer Institute, Great Falls, Montana, United States
Personalized Medicine for Advanced Biliary Cancer Patients
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 800
- Registration Number
- NCT05615818
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven, Leuven, Belgium
🇫🇷CHU Amiens Picardie, Amiens, France
🇫🇷CHU d'Angers, Angers, France
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Kyunghee Burkitt, DO, PhD
- Target Recruit Count
- 21
- Registration Number
- NCT05608369
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT05599984
- Locations
- 🇩🇪
Klinikum der Universität München - Campus Innenstadt /ID# 259412, Munich, Bayern, Germany
🇺🇸Banner MD Anderson Cancer Ctr /ID# 260129, Gilbert, Arizona, United States
🇺🇸City Of Hope Comprehensive Cancer Center /ID# 271295, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.